The FDA approves Portola Pharmaceuticals’ (PTLA -3.2%) application for its next-generation manufacturing process for anticoagulation reversal agent Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo].
The company says the new process will enable it to scale up production and stock hospitals nationwide.
Management will provided additional details on the commercial launch during its corporate webcast on Tuesday, January 8, 2019, at 10:00 am ET.
Trading, currently halted, will resume at 3:40 pm ET.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.